Takeda Pharmaceutical Co Ltd ADR (TAK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Takeda Pharmaceutical Co Ltd ADR (TAK) has a cash flow conversion efficiency ratio of 0.047x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($360.04 Billion) by net assets ($7.65 Trillion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Takeda Pharmaceutical Co Ltd ADR (TAK) liquidity interval to measure how many days the company can operate on defensive assets alone.
Takeda Pharmaceutical Co Ltd ADR - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Takeda Pharmaceutical Co Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Takeda Pharmaceutical Co Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Takeda Pharmaceutical Co Ltd ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Target Corporation
NYSE:TGT
|
0.073x |
|
Public Storage
NYSE:PSA
|
0.079x |
|
Sandvik AB
ST:SAND
|
0.046x |
|
Occidental Petroleum Corporation
NYSE:OXY
|
0.032x |
|
Diamondback Energy Inc
NASDAQ:FANG
|
0.055x |
|
VOLVO B (FRIA) UNSP.ADR
F:VOL4
|
0.056x |
|
SINGAP.TELE. ADR NEW06/10
F:SIT
|
N/A |
|
Samsung Life
KO:032830
|
0.020x |
Annual Cash Flow Conversion Efficiency for Takeda Pharmaceutical Co Ltd ADR (2001–2025)
The table below shows the annual cash flow conversion efficiency of Takeda Pharmaceutical Co Ltd ADR from 2001 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Takeda Pharmaceutical Co Ltd ADR.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $6.94 Trillion | $1.06 Trillion | 0.152x | +54.77% |
| 2024-03-31 | $7.27 Trillion | $716.34 Billion | 0.098x | -35.96% |
| 2023-03-31 | $6.35 Trillion | $977.16 Billion | 0.154x | -22.18% |
| 2022-03-31 | $5.68 Trillion | $1.12 Trillion | 0.198x | +1.20% |
| 2021-03-31 | $5.18 Trillion | $1.01 Trillion | 0.195x | +37.83% |
| 2020-03-31 | $4.73 Trillion | $669.75 Billion | 0.142x | +122.70% |
| 2019-03-31 | $5.16 Trillion | $328.48 Billion | 0.064x | -66.04% |
| 2018-03-31 | $2.02 Trillion | $377.85 Billion | 0.187x | +39.67% |
| 2017-03-31 | $1.95 Trillion | $261.36 Billion | 0.134x | +958.06% |
| 2016-03-31 | $2.01 Trillion | $25.49 Billion | 0.013x | -84.68% |
| 2015-03-31 | $2.21 Trillion | $182.52 Billion | 0.083x | +41.70% |
| 2014-03-31 | $2.54 Trillion | $148.34 Billion | 0.058x | -57.81% |
| 2013-03-31 | $2.22 Trillion | $307.71 Billion | 0.138x | -14.80% |
| 2012-03-31 | $2.07 Trillion | $336.57 Billion | 0.162x | +6.17% |
| 2011-03-31 | $2.14 Trillion | $326.94 Billion | 0.153x | -13.10% |
| 2010-03-31 | $2.16 Trillion | $381.17 Billion | 0.176x | +10.84% |
| 2009-03-31 | $2.05 Trillion | $326.27 Billion | 0.159x | +26.14% |
| 2008-03-31 | $2.32 Trillion | $292.50 Billion | 0.126x | +48.10% |
| 2007-03-31 | $2.46 Trillion | $209.28 Billion | 0.085x | -46.54% |
| 2006-03-31 | $2.35 Trillion | $373.57 Billion | 0.159x | +7.73% |
| 2005-03-31 | $2.00 Trillion | $295.54 Billion | 0.148x | -15.47% |
| 2004-03-31 | $1.78 Trillion | $311.12 Billion | 0.175x | +3.95% |
| 2003-03-31 | $1.57 Trillion | $263.45 Billion | 0.168x | +1.93% |
| 2002-03-31 | $1.46 Trillion | $240.59 Billion | 0.165x | -3.09% |
| 2001-03-31 | $1.25 Trillion | $212.66 Billion | 0.170x | -- |
About Takeda Pharmaceutical Co Ltd ADR
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more